TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT ID: NCT02693535
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
4200 participants
INTERVENTIONAL
2016-03-14
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [email protected], or if a patient, your nearest participating TAPUR site (see participating centers).
\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04550494
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
NCT02567396
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
NCT05253105
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
NCT02014441
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 4 (CDKN2A, CDK4, CDK6)
Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Palbociclib
drug
Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
Sunitinib
drug
Group 6 (mTOR, TSC)
Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations
Temsirolimus
drug
Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Trastuzumab and Pertuzumab
drug
Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
Vemurafenib and Cobimetinib
drug
Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)
Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications
Regorafenib
drug
Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
Olaparib
drug
Group 15 (POLE, POLD1)
Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations
Pembrolizumab
drug
Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
Nivolumab and Ipilimumab
drug
Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Abemaciclib
drug
Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
Talazoparib
drug
Group 20 (ERBB2)
Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression
Atezolizumab and PHESGO
drug
Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval
Atezolizumab and Talazoparib
drug
Group 22 (ROS1 fusion)
Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion
Entrectinib
drug
Group 23 (NTRK amplification)
Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification
Larotrectinib
drug
Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Tucatinib plus Trastuzumab Subcutaneous (SC)
drug
Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation
Futibatinib
drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palbociclib
drug
Sunitinib
drug
Temsirolimus
drug
Trastuzumab and Pertuzumab
drug
Vemurafenib and Cobimetinib
drug
Regorafenib
drug
Olaparib
drug
Pembrolizumab
drug
Nivolumab and Ipilimumab
drug
Abemaciclib
drug
Talazoparib
drug
Atezolizumab and PHESGO
drug
Atezolizumab and Talazoparib
drug
Entrectinib
drug
Larotrectinib
drug
Tucatinib plus Trastuzumab Subcutaneous (SC)
drug
Futibatinib
drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
* Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
1. Absolute neutrophil count ≥ 1.5 x 106/µl
2. Hemoglobin \> 9.0 g/dl
3. Platelets \> 75,000/µl
4. Total bilirubin \< 2.0 mg/ dl, except in patients with Gilbert's Syndrome
5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) \< 2.5 x institutional upper limit of normal (ULN) (or \< 5 x ULN in patients with known hepatic metastases)
6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
* Patients must have disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.
* Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
* Ability to understand and the willingness to sign a written informed consent/assent document.
* Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
* For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
* Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria
* Patients with primary brain tumors or leptomeningeal metastases are excluded.
* Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
* Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Bayer
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Eli Lilly and Company
INDUSTRY
Genentech, Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Pfizer
INDUSTRY
Boehringer Ingelheim
INDUSTRY
Seagen Inc.
INDUSTRY
Taiho Oncology, Inc.
INDUSTRY
American Society of Clinical Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
Cancer Treatment Centers of America-Phoenix
Phoenix, Arizona, United States
Sutter Auburn
Auburn, California, United States
Sutter Alta Bates
Berkeley, California, United States
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California, United States
Kaiser Permanente - Oakland Medical Center
Oakland, California, United States
Sutter Palo Alto Medical Foundation: Palo Alto
Palo Alto, California, United States
Kaiser Permanente - Roseville Medical Center
Roseville, California, United States
Sutter Roseville
Roseville, California, United States
Kaiser Permanente - Sacramento Medical Center
Sacramento, California, United States
Sutter Sacramento
Sacramento, California, United States
Kaiser Permanente - South San Francisco Medical Center
San Francisco, California, United States
California Pacific Medical Center Research Institute
San Francisco, California, United States
Kaiser Permanente - San Francisco Medical Center
San Francisco, California, United States
Sutter Cancer Research Consortium
San Francisco, California, United States
Kaiser Permanente - San Jose Medical Center
San Jose, California, United States
Kaiser Permanente - San Leandro Medical Center
San Leandro, California, United States
Kaiser Permanente - Santa Clara Medical Center
Santa Clara, California, United States
Sutter Palo Alto Medical Foundation: Santa Cruz
Santa Cruz, California, United States
Sutter Palo Alto Medical Foundation: Fremont
Santa Cruz, California, United States
Sutter Palo Alto Medical Foundation: Sunnyvale
Sunnyvale, California, United States
Kaiser Permanente - Vallejo Medical Center
Vallejo, California, United States
Kaiser Permanente - Walnut Creek Medical Center
Walnut Creek, California, United States
Saint Vincent's Medical Center (SVMC)
Bridgeport, Connecticut, United States
Hartford Hospital
Hartford, Connecticut, United States
Midstate Medical Center (MSMC)
Meriden, Connecticut, United States
The Hospital of Central Connecticut (HOCC) Cancer Center
New Britain, Connecticut, United States
William W. Backus Hospital
Norwich, Connecticut, United States
Charlotte Hungerford
Torrington, Connecticut, United States
Windham Hospital (WH)
Willimantic, Connecticut, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Altamonte Springs, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Bonita Springs, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Bradenton, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Brandon, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Cape Coral, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Clearwater, Florida, United States
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Fort Myers, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Fort Myers, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Fort Myers, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Gainesville, Florida, United States
University of Florida Health
Gainesville, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Largo, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Lecanto, Florida, United States
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Naples, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Ocala, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Orange City, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Orlando, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Port Charlotte, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Sarasota, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Sarasota, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
St. Petersburg, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Tampa, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Tavares, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
The Villages, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Trinity, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Venice, Florida, United States
Florida Cancer Specialists South / Sarah Cannon Research Institute
Venice, Florida, United States
Florida Cancer Specialists North / Sarah Cannon Research Institute
Winter Park, Florida, United States
Cancer Treatment Centers of America - Atlanta
Atlanta, Georgia, United States
Emory University Winship Cancer Institute
Atlanta, Georgia, United States
Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
Savannah, Georgia, United States
Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
Savannah, Georgia, United States
Lewis Cancer & Research Pavilion
Savannah, Georgia, United States
Summit Cancer Care
Savannah, Georgia, United States
The Queen's Medical Center - POB I
Honolulu, Hawaii, United States
The Queen's Medical Center - Punchbowl
Honolulu, Hawaii, United States
The Queen's Medical Center - Kuakini
Honolulu, Hawaii, United States
The Queen's Medical Center - West Oahu
‘Ewa Beach, Hawaii, United States
Cancer Treatment Centers of America-Chicago
Chicago, Illinois, United States
Community Health Network (The University of Texas MD Anderson Cancer Center)
Indianapolis, Indiana, United States
Harold Alfond Center for Cancer Care
Augusta, Maine, United States
Jackson Laboratory - Maine Cancer Genomics Initiative
Augusta, Maine, United States
Waldo County General Hospital
Belfast, Maine, United States
SMHC Cancer Care and Blood Disorders -Biddeford
Biddeford, Maine, United States
Northern Light Cancer Care
Brewer, Maine, United States
Raish Peavey Haskell Children's Cancer and Treatment Center
Brewer, Maine, United States
MaineHealth Cancer Care -Brunswick
Brunswick, Maine, United States
New England Cancer Specialist
Kennebunk, Maine, United States
York Hopsital Oncology & Infusion Care in Kittery
Kittery, Maine, United States
Stephens Memorial Hospital
Norway, Maine, United States
Penobscot Bay Medical Center
Rockport, Maine, United States
SMHC Cancer Care and Blood Disorders -Sandford
Sanford, Maine, United States
Maine Children's Cancer Program
Scarborough, Maine, United States
Maine Medical Partner's Women's Health
Scarborough, Maine, United States
New England Cancer Specialist
Scarborough, Maine, United States
MaineHealth Cancer Care -South Portland
South Portland, Maine, United States
New England Cancer Specialist
Topsham, Maine, United States
York Hospital Oncology & Infusion Care in Wells
Wells, Maine, United States
York Hospital Oncology & Infusion Care in York
York Village, Maine, United States
Trinity Health Ann Arbor Hospital
Ann Arbor, Michigan, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Health Saint John Hospital
Detroit, Michigan, United States
Genesys Hurley Cancer Institute
Flint, Michigan, United States
Cancer Research Consortium of West Michigan
Grand Rapids, Michigan, United States
University of Michigan Health - Sparrow Lansing
Lansing, Michigan, United States
Trinity Health Livonia Hospital
Livonia, Michigan, United States
Trinity Health Oakland Hospital
Pontiac, Michigan, United States
MyMichigan Medical Center Saginaw
Saginaw, Michigan, United States
Michigan Cancer Research Consortium
Traverse City, Michigan, United States
Henry Ford Health Warren Hospital
Warren, Michigan, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
NH Oncology - Hematology, PA
Concord, New Hampshire, United States
Solinsky Center for Cancer Care
Manchester, New Hampshire, United States
New England Cancer Specialist
Portsmouth, New Hampshire, United States
Lovelace Medical Center - Saint Joseph Square
Albuquerque, New Mexico, United States
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, United States
The University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
Memorial Medical Center
Las Cruces, New Mexico, United States
Presbyterian Rust Medical Center
Rio Rancho, New Mexico, United States
Northwell Health Monter Cancer Center
Lake Success, New York, United States
Northern Westchester Hospital
Mount Kisco, New York, United States
Cohen Children's Medical Center
New Hyde Park, New York, United States
Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Manhattan Eye, Ear, and Throat Hospital
New York, New York, United States
Staten Island University Hospital
New York, New York, United States
Queens Cancer Center
Rego Park, New York, United States
Phelps Hospital
Sleepy Hollow, New York, United States
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Atrium Health's Levine Cancer Institute
Charlotte, North Carolina, United States
Sanford Health- Bismarck
Bismarck, North Dakota, United States
Sanford Health- Fargo
Fargo, North Dakota, United States
University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Kettering Health
Kettering, Ohio, United States
West Chester Hospital
West Chester, Ohio, United States
Providence Health & Services
Portland, Oregon, United States
Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, United States
Lehigh Valley Hospital- Muhlenberg
Bethlehem, Pennsylvania, United States
Pocono Medical Center
East Stroudsburg, Pennsylvania, United States
Lehigh Valley Hospital-Hazleton
Hazleton, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
SC Cancer Specialists at St. Joseph's/Candler Bluffton
Bluffton, South Carolina, United States
St. Joseph's/Candler Smith
Bluffton, South Carolina, United States
Summit Cancer Care at St. Josph's/Candler Bluffton
Bluffton, South Carolina, United States
South Carolina Cancer Specialists
Hilton Head Island, South Carolina, United States
Sanford Cancer Center Oncology Clinic and Pharmacy
Sioux Falls, South Dakota, United States
Tennessee Oncology - Nashville / Sarah Cannon Research Institute
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
Cedar City, Utah, United States
Intermountain Healthcare
Salt Lake City, Utah, United States
Dixie Regional Medical Center-River Road Campus
St. George, Utah, United States
Inova Schar Cancer Institute
Fairfax, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
Aurora Cancer Care - Burlington
Burlington, Wisconsin, United States
Aurora Health Care - Germantown Health Center
Germantown, Wisconsin, United States
Aurora Cancer Care - Grafton
Grafton, Wisconsin, United States
Aurora BayCare Medical Center
Green Bay, Wisconsin, United States
Aurora Cancer Care - Kenosha South
Kenosha, Wisconsin, United States
Aurora Bay Area Medical Center
Marinette, Wisconsin, United States
Aurora Cancer Care Milwaukee
Milwaukee, Wisconsin, United States
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States
Aurora Sinai Medical Center
Milwaukee, Wisconsin, United States
Aurora West Allis Medical Center
Milwaukee, Wisconsin, United States
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin, United States
Aurora Cancer Care - Racine
Racine, Wisconsin, United States
Vince Lombardi Cancer Center
Sheboygan, Wisconsin, United States
Aurora Medical Center in Summit
Summit, Wisconsin, United States
Vince Lombardi Cancer Clinic - Two Rivers
Two Rivers, Wisconsin, United States
Aurora Cancer Care - Milwaukee West
Wauwatosa, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: backup
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00014171
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.